Disclosed herein is the use of eslicarbazepine or eslicarbazepine acetate in the manufacture of a medicament for treating a condition selected from epilepsy central and peripheral nervous system disorders affective disorders schizoaffective disorders bipolar disorders attention disorders anxiety disorders neuropathic pain and neuropathic pain-related disorders sensorimotor disorders vestibular disorders and nervous function alterations in degenerative and post-ischemic diseases in circumstances where the patient to be treated has previously been treated with a medicament that is a substrate for P-glycoprotein or Multiple Resistance Proteins.
